专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明授权

US09028870B2 Hydrogel-driven drug dosage form 有权
标题翻译：水凝胶驱动药物剂型
公开(公告)号：US09028870B2
公开(公告)日：2015-05-12
申请号：US12979278
申请日：2010-12-27
申请人： Leah E. Appel , Ronald A. Beyerinck , Mark B. Chidlaw , William J. Curatolo , Dwayne T. Friesen , Kelly L. Smith , Avinash G. Thombre
发明人： Leah E. Appel , Ronald A. Beyerinck , Mark B. Chidlaw , William J. Curatolo , Dwayne T. Friesen , Kelly L. Smith , Avinash G. Thombre
IPC分类号： A61K9/00
CPC分类号： A61K9/0004
摘要： A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.
摘要翻译：控释剂型具有涂覆的核心，其核心包含含药物的组合物和水溶胀性组合物，每个组合物占据核心内的分开的区域。含药组合物包含低溶解度药物和药物引诱剂。芯周围的涂层是透水的，不溶于水的，并且具有至少一个通过其的输送口。公开了具有特定药物释放曲线的多种制剂。

52. 发明授权

US08883209B2 Pharmaceutical solid dispersions 有权
标题翻译：药物固体分散体
公开(公告)号：US08883209B2
公开(公告)日：2014-11-11
申请号：US12760393
申请日：2010-05-25
申请人： Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Ravi M. Shanker
发明人： Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Ravi M. Shanker
IPC分类号： A61K31/404 , A61K9/16 , A61K9/14
CPC分类号： A61K9/1635 , A61K9/146 , A61K9/1652
摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.
摘要翻译：组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。分散体中药物的至少大部分是无定形的。聚合物的玻璃化转变温度至少为100℃，相对湿度为百分之五十。本发明的另一方面包括相同的组成，不同之处在于分散体在50％的相对湿度下具有至少50℃的玻璃化转变温度。在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。分散体中药物的至少大部分是无定形的。组合物还包括增加使用环境中药物浓度的浓度增强聚合物。稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

53. 发明授权

US08481081B2 Pharmaceutical solid dispersions 有权
标题翻译：药物固体分散体
公开(公告)号：US08481081B2
公开(公告)日：2013-07-09
申请号：US10459808
申请日：2003-06-10
申请人： Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Ravi M. Shanker
发明人： Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Ravi M. Shanker
IPC分类号： A61K9/14
CPC分类号： A61K9/1635 , A61K9/146 , A61K9/1652
摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.
摘要翻译：组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。分散体中药物的至少大部分是无定形的。聚合物的玻璃化转变温度至少为100℃，相对湿度为百分之五十。本发明的另一方面包括相同的组成，不同之处在于分散体在50％的相对湿度下具有至少50℃的玻璃化转变温度。在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。分散体中药物的至少大部分是无定形的。组合物还包括增加使用环境中药物浓度的浓度增强聚合物。稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

54. 发明授权

US08236328B2 Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers 有权
标题翻译：与聚合物混合的无定形药物的分散体的药物组合物
公开(公告)号：US08236328B2
公开(公告)日：2012-08-07
申请号：US12217700
申请日：2008-07-08
申请人： Walter C. Babcock , William J. Curatolo , Dwayne T. Friesen , Rodney J. Ketner , Julian B. Lo , James A. S. Nightingale , Ravi M. Shanker , James B. West
发明人： Walter C. Babcock , William J. Curatolo , Dwayne T. Friesen , Rodney J. Ketner , Julian B. Lo , James A. S. Nightingale , Ravi M. Shanker , James B. West
IPC分类号： A61K9/00 , A61K9/14
CPC分类号： A61K9/146
摘要： A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.
摘要翻译：药物组合物包含包含低溶解度药物和与浓度增强聚合物组合的基质的分散体。至少大部分药物在分散体中是无定形的。组合物改善药物在分散体中的稳定性和/或药物在使用环境中的浓度。

55. 发明授权

US08202912B2 Pharmaceutical compositions providing enhanced drug concentrations 有权
标题翻译：提供增强药物浓度的药物组合物
公开(公告)号：US08202912B2
公开(公告)日：2012-06-19
申请号：US13208305
申请日：2011-08-11
申请人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
发明人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
IPC分类号： A61K47/32 , A61K9/14 , A61K9/16 , A61K9/22
CPC分类号： A61K47/38 , A61K9/146 , A61K9/1629 , A61K9/1652 , A61K31/135 , A61K31/404 , A61K31/4178 , A61K31/4375 , A61K31/496 , A61K31/517
摘要： A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
摘要翻译：将溶解度改善形式的药物与足够量的浓度增强聚合物组合，使得组合在使用环境中相对于包含相同量的相同溶解度改善形式的药物的对照提供了显着增强的药物浓度没有浓度增强聚合物。

56. 发明授权

US08147872B2 Pharmaceutical compositions of drugs and neutralized acidic polymers 有权
标题翻译：药物的药物组合物和中和的酸性聚合物
公开(公告)号：US08147872B2
公开(公告)日：2012-04-03
申请号：US11213118
申请日：2005-08-26
申请人： Marshall Crew , Dwayne T. Friesen , Rodney J. Ketner , Ravi M. Shanker , James B. West
发明人： Marshall Crew , Dwayne T. Friesen , Rodney J. Ketner , Ravi M. Shanker , James B. West
IPC分类号： A61K9/14 , A61K9/00 , A61K31/716
CPC分类号： A61K9/1611 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1652 , A61K31/00 , A61K31/404 , A61K31/405 , A61K31/4439 , A61K31/4706 , A61K31/4745 , A61K31/496 , A61K31/498 , A61K31/7024 , A61K31/717 , A61K2300/00
摘要： Pharmaceutical compositions comprised of low-solubility and/or acid-sensitive drugs and neutralized acidic polymers are disclosed.
摘要翻译：公开了由低溶解度和/或酸敏感性药物和中和的酸性聚合物组成的药物组合物。

57. 发明授权

US08026286B2 Pharmaceutical compositions providing enhanced drug concentrations 有权
标题翻译：提供增强药物浓度的药物组合物
公开(公告)号：US08026286B2
公开(公告)日：2011-09-27
申请号：US09742785
申请日：2000-12-20
申请人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
发明人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
IPC分类号： A61K47/32 , A61K9/14 , A61K9/16 , A61K9/22
CPC分类号： A61K47/38 , A61K9/146 , A61K9/1629 , A61K9/1652 , A61K31/135 , A61K31/404 , A61K31/4178 , A61K31/4375 , A61K31/496 , A61K31/517
摘要： A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
摘要翻译：将溶解度改善形式的药物与足够量的浓度增强聚合物组合，使得组合在使用环境中相对于包含相同量的相同溶解度改善形式的药物的对照提供了显着增强的药物浓度没有浓度增强聚合物。

58. 发明申请

US20100256110A1 PHARMACEUTICAL SOLID DISPERSIONS 有权
标题翻译：药物固体分散体
公开(公告)号：US20100256110A1
公开(公告)日：2010-10-07
申请号：US12760393
申请日：2010-05-25
申请人： Walter C. Babcock , Dwayne T. Friesen , James A.S. Nightingale , Ravi M. Shanker
发明人： Walter C. Babcock , Dwayne T. Friesen , James A.S. Nightingale , Ravi M. Shanker
IPC分类号： A61K31/404 , A61K31/44 , A61P9/12 , A61P7/02 , A61P3/10 , A61P35/00 , A61P15/10 , A61P29/00 , A61P25/18 , A61P31/04 , A61P31/10 , A61P25/16 , A61P25/28 , A61P31/12
CPC分类号： A61K9/1635 , A61K9/146 , A61K9/1652
摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.
摘要翻译：组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。分散体中药物的至少大部分是无定形的。聚合物的玻璃化转变温度至少为100℃，相对湿度为百分之五十。本发明的另一方面包括相同的组成，不同之处在于分散体在50％的相对湿度下具有至少50℃的玻璃化转变温度。在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。分散体中药物的至少大部分是无定形的。组合物还包括增加使用环境中药物浓度的浓度增强聚合物。稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

59. 发明授权

US07235260B2 Pharmaceutical compositions of a sparingly soluble glycogen phosphorylase inhibitor 有权
标题翻译：一种微溶糖原磷酸化酶抑制剂的药物组合物
公开(公告)号：US07235260B2
公开(公告)日：2007-06-26
申请号：US10393549
申请日：2003-03-21
申请人： Marshall D. Crew , Dwayne T. Friesen , Bruno C. Hancock , Chris Macri , James A. S. Nightingale , Ravi M. Shankar
发明人： Marshall D. Crew , Dwayne T. Friesen , Bruno C. Hancock , Chris Macri , James A. S. Nightingale , Ravi M. Shankar
IPC分类号： A61K9/14 , A61K9/16 , A61K9/50
CPC分类号： A61K9/146 , A61K9/1652 , A61K9/2077 , A61K31/404
摘要： Pharmaceutical compositions of a particularly effective sparingly soluble glycogen phosphorylase inhibitor are disclosed, as well as methods of making such compositions and dosage forms from such compositions.
摘要翻译：公开了特别有效的微溶糖原磷酸化酶抑制剂的药物组合物，以及从这些组合物制备这些组合物和剂型的方法。

60. 发明授权

US06623639B2 Solvent-resistant microporous polybenzimidazole membranes 有权
标题翻译：耐溶剂微孔聚苯并咪唑膜
公开(公告)号：US06623639B2
公开(公告)日：2003-09-23
申请号：US09525580
申请日：2000-03-15
申请人： Robert P. Barss , Dwayne T. Friesen , Scott B. McCray , Kendall R. Pearson , Roderick J. Ray , Delores R. Sidwell , James B. West
发明人： Robert P. Barss , Dwayne T. Friesen , Scott B. McCray , Kendall R. Pearson , Roderick J. Ray , Delores R. Sidwell , James B. West
IPC分类号： B01D6908
CPC分类号： B01D67/0093 , B01D67/0006 , B01D67/0011 , B01D69/08 , B01D69/12 , B01D69/125 , B01D71/56 , B01D71/62 , B01D2323/08 , B01D2323/30 , B65D85/812 , B65D2205/02
摘要： Solvent-resistant polybenzimidazole membranes, methods of making them and crosslinking them and composite membranes and hollow fiber membrane modules from them are disclosed.
摘要翻译：公开了耐溶剂聚苯并咪唑膜，制备它们并交联它们的方法以及复合膜和中空纤维膜组件。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式